These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28668865)

  • 1. Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy.
    Detti B; D'Angelillo RM; Ingrosso G; Olmetto E; Francolini G; Triggiani L; Bruni A; Borghesi S; Fondelli S; Carfagno T; Santini R; Santoni R; Trodella LE; Livi L
    Anticancer Res; 2017 Jul; 37(7):3717-3722. PubMed ID: 28668865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
    Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
    Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
    Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Line of abiraterone acetate in castration-resistant metastatic prostate cancer--Does it matter? report of a multi-institutional experience.
    Gunduz S; Bozcuk H; Yıldız M; Goksu SS; Uysal M; Arslan D; Tatlı AM; Mutlu H; Coşkun HS; Ozdogan M
    Indian J Cancer; 2015; 52(4):658-60. PubMed ID: 26960509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone.
    Conteduca V; Caffo O; Derosa L; Veccia A; Petracci E; Chiuri VE; Santoni M; Santini D; Fratino L; Maines F; Testoni S; De Giorgi U
    Prostate; 2015 Sep; 75(12):1329-38. PubMed ID: 25982919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone.
    Manokumar T; Aziz S; Breunis H; Rizvi SF; Joshua AM; Tannock IF; Alibhai SM
    J Geriatr Oncol; 2016 Mar; 7(2):81-9. PubMed ID: 26853769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience.
    Liu Y; Long W; Zhang Z; Mai L; Huang S; Liu B; Cao W; Wu J; Zhou F; Li Y; He L
    Radiat Oncol; 2021 Jan; 16(1):5. PubMed ID: 33407637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
    Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
    Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials.
    Wang Y; Zhang H; Shen W; He P; Zhou Z
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1751-1768. PubMed ID: 29797220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
    Conteduca V; Caffo O; Fratino L; Lo Re G; Basso U; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Zagonel V; Veccia A; Lolli C; Maines F; De Giorgi U
    Future Oncol; 2015; 11(21):2881-91. PubMed ID: 26436290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer.
    Burgio SL; Conteduca V; Rudnas B; Carrozza F; Campadelli E; Bianchi E; Fabbri P; Montanari M; Carretta E; Menna C; De Giorgi U
    Clin Genitourin Cancer; 2015 Feb; 13(1):39-43. PubMed ID: 24999168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.
    Maines F; Caffo O; De Giorgi U; Fratino L; Lo Re G; Zagonel V; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Basso U; Fraccon AP; Vicario G; Conteduca V; Galligioni E
    Clin Genitourin Cancer; 2016 Feb; 14(1):48-55. PubMed ID: 26382222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer?
    Davies RS; Smith C; Button MR; Tanguay J; Barber J; Palaniappan N; Staffurth J; Lester JF
    Anticancer Res; 2015 Oct; 35(10):5615-21. PubMed ID: 26408734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
    Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF
    BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole.
    Leibowitz-Amit R; Seah JA; Atenafu EG; Templeton AJ; Vera-Badillo FE; Alimohamed N; Knox JJ; Tannock IF; Sridhar SS; Joshua AM
    Eur J Cancer; 2014 Sep; 50(14):2399-407. PubMed ID: 25042152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate.
    Boegemann M; Schlack K; Fischer AK; Gerß J; Steinestel J; Semjonow A; Schrader AJ; Krabbe LM
    PLoS One; 2016; 11(9):e0161959. PubMed ID: 27583544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France.
    Bonnet C; Boudou-Rouquette P; Azoulay-Rutman E; Huillard O; Golmard JL; Carton E; Noé G; Vidal M; Orvoen G; Chah Wakilian A; Villeminey C; Blanchet B; Alexandre J; Goldwasser F; Thomas-Schoemann A
    Cancer Chemother Pharmacol; 2017 May; 79(5):1051-1055. PubMed ID: 28361167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer.
    Schlack K; Krabbe LM; Fobker M; Schrader AJ; Semjonow A; Boegemann M
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27618028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.
    Boegemann M; Schlack K; Thomes S; Steinestel J; Rahbar K; Semjonow A; Schrader AJ; Aringer M; Krabbe LM
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.